Topic: manufacturing plant
Some generics makers are responding to industrywide pricing pressure by bulking up via M&A. Not Novartis.
Generic API maker Cambrex said it will begin a $3.5 million project to improve wastewater processing capabilities at its facility in Sweden.
BiodVax will test its universal flu vaccine candidate M-001 as a standalone shot after it elicited positive immune responses as a primer in a phase 2b trial.
Takeda is relocating hundreds of jobs, a key Velcade patent was restored till 2022, 36 drugs were added to China's insurance drug list after huge discounts.
Emergent BioSolutions has snapped up the only FDA-approved smallpox vaccine from Sanofi Pasteur.
Celgene buys Beigene’s PD-1 inhibitor, Fosun stumbles over rumors about its chairman, Neopharma expands in Japan and Abu Dhabi, and more.
China’s FDA joined ICH, Takeda completed new solid dosage plant, the FDA bans imports of Ipca drugs.
Drug-delivery specialist Aptar Pharma is beefing up capacity at a New York plant to bring supplies of a key product closer to U.S. customers.
BioMarin’s Cork, Ireland, bulk biologic manufacturing facility has FDA approval to produce an ingredient of Vimizim used to treat Morquio syndrome.
Takeda is starting work on a €40 million plant to manufacture multiple myeloma drug Ninlaro at its site in Ireland, where it will add 40 new jobs.